The clinical investigation continues at the Baney research facility on Bioko Island, Equatorial Guinea where the country's second trial of the Sanaria's PfSPZ® malaria vaccine is being conducted. The study team welcomed the Ambassador of United States in Equatorial Guinea Ms. Julie Furuta-Toy, along with representatives of the private funding partners sponsoring the trial, Mr. James Crawford, Resident Manager at Marathon EG Production Ltd., Dr. Carl Maas, Marathon's Corporate Social Responsibility Manager, Mr. Paul Moschell, President, and Mr. Jim O'Casek, Resident Manager at AMPCO , Mr. Thor Pruckl, Resident Manager for Noble Energy, and Mr. Ken McGhee, Noble's Corporate Social Responsibility Manager.

They were received by Principal Investigator, Dr. Ally Olotu of Ifakara Health Institute (IHI), who gave a brief background on the Equato-Guinean Malaria Vaccine Initiative (EGMVI) project as well as an update on the current status of the Phase II clinical trial. The visitors also met Dr. Thomas Richie, Chief Medical Officer for Sanaria, Inc., Dr. Peter Billingsley, Vice President of International Research at Sanaria, Dr. Salim Abdullah, former Director IHI, Mr. Wonder Philip Phiri, Chief of Party for Medical Care Development International (MCDI). Dr. Steve Manock, Sanaria's field physician, led the tour of the facility with assistance from a variety of Equatoguinean clinical, nursing and field team members, led by Dr. Vicente Urbano, the lead physician for the Equato-Guinean Ministry of Health and Social Welfare, explaining each component within the trial from recruitment to nursing and pharmacy, to volunteer observation and care.